Ad-E6/7-HR vaccine improves the prophylactic and therapeutic efficacy in HPV-associated cancers

Abstract

Background: High-risk human papillomavirus (HPV), especially HPV16, is closely correlated with certain cancers. E6 and E7 proteins of HPV16 play critical roles in oncogenesis, making them optimal targets for treating HPV-associated cancers. Here, we engineered an innovative vaccine, Ad-E6/7-HR, designed to evoke immune responses through the incorporation of self-assembling heptad-repeat 1 (HR1) and HR2 originated from Severe acute respiratory syndrome coronavirus 2.

Methods: Ad-E6/7-HR was constructed utilising a replication-defective human adenovirus serotype 5 vector and evaluated its immunogenicity and therapeutic efficacy in murine models. We verified the antitumour efficacy of the vaccine in TC-1 subcutaneous and pulmonary models. Flow cytometry, enzyme-linked immunospot assay, and immunofluorescence staining were used to assess the cellular immunogenicity of Ad-E6/7-HR.

Results: Ad-E6/7-HR induced robust immune responses, significantly increasing antigen-specific CD8⁺ T cells. The vaccine also enhanced memory T-cell generation and induced potent cytokine secretion, as exemplified by interferon-γ and tumour necrosis factor-α. Ad-E6/7-HR conferred complete protection against tumour growth in the prophylactic model. In therapeutic settings, Ad-E6/7-HR significantly reduced tumour size and improved survival. Furthermore, Ad-E6/7-HR reshaped the tumour microenvironment by increased CD8⁺ T-cell recruitment and reduced immunosuppressive cells, like myeloid-derived suppressor cells and M2 macrophages, thereby enhancing antitumour immunity.

Conclusions: By targeting HPV16 E6 and E7 proteins and leveraging the self-assembling HR1 and HR2 sequences to enhance immune responses, Ad-E6/7-HR represented a promising candidate for preventing and treating HPV-associated cancers. Further clinical investigation is warranted to evaluate its potential in human trials.

Keywords

adenovirus vaccine / cellular immunity / human-papillomavirus-associated cancers / oncology

References

[1] Jensen JE, Becker GL, Jackson JB, Rysavy MB. Human papillomavirus and associated cancers: a review. Viruses. 2024; 16(5): 680.

[2] Tian R, Liu J, Fan W, et al. Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6/E7 genes in cervical cancer cells. Mol Ther Oncolytics. 2022; 24: 171-179.

[3] Bhattacharjee R, Das SS, Biswal SS, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol. 2022; 174: 103675.

[4] Williamson AL. recent developments in human papillomavirus (HPV) vaccinology. Viruses. 2023; 15(7): 1440.

[5] Martinez-Zapien D, Ruiz FX, Poirson J, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016; 529(7587): 541-545.

[6] Wei H, Qu L, Dai S, et al. Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. Nat Commun. 2021; 12(1): 2280.

[7] Zhou L, Ng DS, Yam JC, et al. Post-translational modifications on the retinoblastoma protein. J Biomed Sci. 2022; 29(1): 33.

[8] Mir BA, Ahmad A, Farooq N, et al. Increased expression of HPV-E7 oncoprotein correlates with a reduced level of pRb proteins via high viral load in cervical cancer. Sci Rep. 2023; 13(1): 15075.

[9] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12-49.

[10] Yousefi Z, Aria H, Ghaedrahmati F, et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy. Front Immunol. 2021; 12: 805695.

[11] Skolnik JM, Morrow MP. Vaccines for HPV-associated diseases. Mol Aspects Med. 2023; 94: 101224.

[12] Mo Y, Ma J, Zhang H, et al. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. Front Cell Infect Microbiol. 2022; 12: 909223.

[13] Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol. 2018; 47: 59-72.

[14] Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol. 2022; 19(9): 993-1011.

[15] Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology. 2021; 19(1): 59.

[16] Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19(3): 141-154.

[17] Guo L, Lin S, Chen Z, Cao Y, He B, Lu G. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal Transduct Target Ther. 2023; 8(1): 197.

[18] Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4): 343-355.

[19] Pang W, Lu Y, Zhao YB, et al. A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein. Cell Res. 2022; 32(12): 1068-1085.

[20] He C, Yang J, Hong W, et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun. 2022; 13(1): 5459.

[21] Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021; 184(6): 1589-1603.

[22] Chang J. Adenovirus vectors: excellent tools for vaccine development. Immune Netw. 2021; 21(1): e6.

[23] Watanabe M, Nishikawaji Y, Kawakami H, Kosai KI. Adenovirus biology, recombinant adenovirus, and adenovirus usage in gene therapy. Viruses. 2021; 13(12): 2502.

[24] Dumitrescu M, Trusca VG, Fenyo IM, Gafencu AV. An efficient method for adenovirus production. J Vis Exp. 2021(172).

[25] Sallard E, Zhang W, Aydin M, Schröer K, Ehrhardt A. The adenovirus vector platform: novel insights into rational vector design and lessons learned from the COVID-19 vaccine. Viruses. 2023; 15(1): 204.

[26] Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017; 13(3): 613-620.

[27] Chai P, Shi Y, Yu J, et al. The central conserved peptides of respiratory syncytial virus G protein enhance the immune response to the RSV F protein in an adenovirus vector vaccine candidate. Vaccines (Basel). 2024; 12(7): 807.

[28] Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240): 1845-1854.

[29] Snook AE, Baybutt TR, Xiang B, et al. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019; 7(1): 104.

[30] Bilusic M, McMahon S, Madan RA, et al. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021; 9(3): e002374.

[31] Zhu F, Lu Z, Tang W, et al. Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors. J Immunother Cancer. 2024; 12(8): e009869.

[32] Vujadinovic M, Khan S, Oosterhuis K, et al. Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. Vaccine. 2018; 36(30): 4462-4470.

[33] Wan B, Qin L, Ma W, Wang H. Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine. Infect Agent Cancer. 2022; 17(1): 5.

[34] Sun H, Li Y, Liu P, et al. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerg Microbes Infect. 2020; 9(1): 1238-1241.

[35] Cibrián D, Sánchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017; 47(6): 946-953.

[36] Gebhardt T, Park SL, Parish IA. Stem-like exhausted and memory CD8(+) T cells in cancer. Nat Rev Cancer. 2023; 23(11): 780-798.

[37] Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal JA, Perán M, Giovannetti E. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024; 17(1): 44.

[38] Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol. 2024; 21(2): 147-164.

[39] Fakhr E, Modic Ž, Cid-Arregui A. Recent developments in immunotherapy of cancers caused by human papillomaviruses. Immunology. 2021; 163(1): 33-45.

[40] Abu-Rustum NR, Yashar CM, Arend R, et al. NCCN Guidelines® Insights: cervical Cancer, Version 1.2024. J Natl Compr Canc Netw. 2023; 21(12): 1224-1233.

[41] Randall LM, Walker AJ, Jia AY, Miller DT, Zamarin D. Expanding our impact in cervical cancer treatment: novel immunotherapies, radiation innovations, and consideration of rare histologies. Am Soc Clin Oncol Educ Book. 2021; 41: 252-263.

[42] Chua BWB, Ma VY, Alcántar-Fernández J, Wee HL. Is it time to genotype beyond HPV16 and HPV18 for cervical cancer screening? Int J Public Health. 2022; 67: 1604621.

[43] Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024; 404(10451): 435-444.

[44] Boursnell ME, Rutherford E, Hickling JK, et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine. 1996; 14(16): 1485-1494.

[45] Nordfors C, Grün N, Tertipis N, et al. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer. 2013; 49(11): 2522-2530.

[46] Tang Y, Zhang AXJ, Chen G, Wu Y, Gu W. Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives. Mol Ther Oncolytics. 2021; 22: 410-430.

[47] Ramos da Silva J, Ramos Moreno AC, Silva Sales N, et al. A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model. Oncoimmunology. 2021; 10(1): 1949896.

[48] Cheng WF, Hung CF, Lin KY, et al. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther. 2003; 10(16): 1311-1320.

[49] Shan Y, Ding Z, Cui Z, Chen A. Incidence, prognostic factors and a nomogram of cervical cancer with distant organ metastasis: a SEER-based study. J Obstet Gynaecol. 2023; 43(1): 2181690.

[50] Haring CT, Kana LA, Dermody SM, et al. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols. Cancer. 2023; 129(18): 2817-2827.

[51] Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P. Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct Target Ther. 2025; 10(1): 44.

[52] Mercuri M, Hackett K, Barnabas RV, Emerson CI. Evaluation of a single-dose HPV vaccine strategy for promoting vaccine, health, and gender equity. Lancet Infect Dis. 2024; 24(10): e654-e658.

[53] Wieking BG, Vermeer DW, Spanos WC, et al. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 2012; 19(10): 667-674.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.